期刊
ANTIBIOTICS-BASEL
卷 10, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/antibiotics10101185
关键词
Klebsiella pneumoniae; siderophore; cephalosporin
资金
- LegoChem BioSciences, Inc
Klebsiella pneumoniae is a significant clinical pathogen causing various infections, with growing concern over multidrug-resistant strains. The novel antibiotic LCB10-0200, a siderophore-conjugated cephalosporin, demonstrated potent antibacterial activity against K. pneumoniae in vitro and in vivo, surpassing ceftazidime in efficacy. These findings highlight the potential of LCB10-0200 as a promising antibacterial agent against K. pneumoniae infections.
Klebsiella pneumoniae is one of the important clinical organisms that causes various infectious diseases, including urinary tract infections, necrotizing pneumonia, and surgical wound infections. The increase in the incidence of multidrug-resistance K. pneumoniae is a major problem in public healthcare. Therefore, a novel antibacterial agent is needed to treat this pathogen. Here, we studied the in vitro and in vivo activities of a novel antibiotic LCB10-0200, a siderophore-conjugated cephalosporin, against clinical isolates of K. pneumoniae. In vitro susceptibility study found that LCB10-0200 showed potent antibacterial activity against K. pneumoniae, including the beta-lactamase producing strains. The in vivo efficacy of LCB10-0200 was examined in three different mouse infection models, including systemic, thigh, and urinary tract infections. LCB10-0200 showed more potent in vivo activity than ceftazidime in the three in vivo models against the drug-susceptible and drug-resistant K. pneumoniae strains. Taken together, these results show that LCB10-0200 is a potential antibacterial agent to treat infection caused by K. pneumoniae.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据